Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer, Secondary cancers
Closed
Phase 1/2
This study is looking at durvalumab and paclitaxel combined with other cancer drugs for triple negative breast cancer that has spread.
Triple negative breast cancer is breast cancer that has no receptors for:
the hormone
the hormone
the protein
Recruitment start: 4 February 2020
Recruitment end: 13 May 2024
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
AstraZeneca
Last reviewed: 24 Jul 2024
CRUK internal database number: 15921
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
